Elevance Health, Inc. (ELV)
NYSE: ELV · Real-Time Price · USD
362.74
+6.61 (1.86%)
At close: Apr 28, 2026, 4:00 PM EDT
362.00
-0.74 (-0.20%)
After-hours: Apr 28, 2026, 7:25 PM EDT
Elevance Health Stock Forecast
Stock Price Forecast
The 18 analysts with 12-month price forecasts for Elevance Health stock have an average target of 379.94, with a low estimate of 310 and a high estimate of 478. The average target predicts an increase of 4.74% from the current stock price of 362.74.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Elevance Health stock from 19 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 5 |
| Buy | 6 | 6 | 7 | 7 | 7 | 6 |
| Hold | 6 | 7 | 7 | 7 | 7 | 8 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 16 | 17 | 18 | 18 | 18 | 19 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JP Morgan | JP Morgan | Buy Maintains $397 → $411 | Buy | Maintains | $397 → $411 | +13.30% | Apr 28, 2026 |
| Barclays | Barclays | Buy Maintains $393 → $408 | Buy | Maintains | $393 → $408 | +12.48% | Apr 24, 2026 |
| Guggenheim | Guggenheim | Strong Buy Maintains $396 → $399 | Strong Buy | Maintains | $396 → $399 | +10.00% | Apr 24, 2026 |
| Evercore ISI Group | Evercore ISI Group | Hold Maintains $345 → $360 | Hold | Maintains | $345 → $360 | -0.76% | Apr 23, 2026 |
| Baird | Baird | Hold Maintains $317 → $331 | Hold | Maintains | $317 → $331 | -8.75% | Apr 23, 2026 |
Financial Forecast
Revenue This Year
194.84B
from 199.13B
Decreased by -2.15%
Revenue Next Year
200.82B
from 194.84B
Increased by 3.07%
EPS This Year
26.17
from 25.21
Increased by 3.82%
EPS Next Year
29.55
from 26.17
Increased by 12.89%
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 215.1B | 220.5B | |||
| Avg | 194.8B | 200.8B | |||
| Low | 183.3B | 190.4B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 8.0% | 13.2% | |||
| Avg | -2.2% | 3.1% | |||
| Low | -8.0% | -2.3% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 29.42 | 33.62 | ||||||
| Avg | 26.17 | 29.55 | ||||||
| Low | 24.90 | 27.81 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 16.7% | 28.5% | ||||||
| Avg | 3.8% | 12.9% | ||||||
| Low | -1.2% | 6.3% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.